Clearside Biomedical is an ophthalmic company specializing in the research, development and commercialization of therapeutic products through a proprietary ocular microinjection platform that targets the individual compartments of the eye. Currently, Clearside Biomedical is focused on its initial product candidate, CLS1001, under development for retinal applications through the delivery of proven therapeutics to the suprachoroidal space.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/05/12 | $4,000,000 | Series A |
Hatteras Venture Partners | undisclosed |
| 01/31/13 | $7,900,000 |
Santen | undisclosed | |
| 09/02/14 | $16,000,000 | Series B |
Georgia Research Alliance Hatteras Venture Partners Mountain Group Capital RUSNANO Santen Pharmaceuticals | undisclosed |
